Market open
Seres Therapeutics/$MCRB
13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX
About Seres Therapeutics
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
Ticker
$MCRB
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
103
ISIN
US81750R2013
Website
MCRB Metrics
BasicAdvanced
$65M
0.83
$8.98
2.88
-
Price and volume
Market cap
$65M
Beta
2.88
52-week high
$10.55
52-week low
$6.53
Financial strength
Current ratio
2.11
Quick ratio
1.967
Long term debt to equity
159.515
Total debt to equity
177.446
Management effectiveness
Return on assets (TTM)
-28.22%
Return on equity (TTM)
1,298.09%
Valuation
Price to earnings (TTM)
0.825
Price to book
1.28
Price to tangible book (TTM)
1.28
Price to free cash flow (TTM)
-0.693
Growth
Earnings per share change (TTM)
-172.24%
3-year earnings per share growth (CAGR)
-21.95%
MCRB News
AllArticlesVideos
Seres Therapeutics, Inc. (MCRB) Q1 2025 Earnings Call Transcript
Seeking Alpha·1 week ago
Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases
GlobeNewsWire·2 weeks ago
Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Seres Therapeutics stock?
Seres Therapeutics (MCRB) has a market cap of $65M as of May 16, 2025.
What is the P/E ratio for Seres Therapeutics stock?
The price to earnings (P/E) ratio for Seres Therapeutics (MCRB) stock is 0.83 as of May 16, 2025.
Does Seres Therapeutics stock pay dividends?
No, Seres Therapeutics (MCRB) stock does not pay dividends to its shareholders as of May 16, 2025.
When is the next Seres Therapeutics dividend payment date?
Seres Therapeutics (MCRB) stock does not pay dividends to its shareholders.
What is the beta indicator for Seres Therapeutics?
Seres Therapeutics (MCRB) has a beta rating of 2.88. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.